Unassociated Document

Aggregate Principal Amount		$3,800,000

Underlying Shares		Shares of the iShares^®Nasdaq Biotechnology Index Fund

Pricing Date		September 21, 2007

Original Issue Date (Settlement Date)		September 28, 2007

Maturity Date		December 20, 2008, subject to postponement in accordance with the following paragraph in the event of a Market Disruption Event on the scheduled Valuation Date.

		If due to a Market Disruption Event or otherwise, the Valuation Date is postponed so that it falls less than two scheduled Trading Days prior to the scheduled Maturity Date, the Maturity Date will be the second scheduled Trading Day following the Valuation Date as postponed. See “—Valuation Date” below.

Issue Price		$10 per PLUS

Stated Principal Amount		$10 per PLUS

Denominations		$10 and integral multiples thereof

CUSIP Number		617475744

Interest Rate		None

Specified Currency		U.S. dollars

Payment at Maturity		At maturity, upon delivery of the PLUS to the Trustee, we will pay with respect to each $10 Stated Principal Amount an amount in cash equal to: (i) if the Final Share Price is greater than the Initial Share Price, the lesser of (a) $10 plus the Leveraged Upside Payment and (b) the Maximum Payment at Maturity or (ii) if the Final Share Price is less than or equal to the Initial Share Price, $10 times the Share Performance Factor. See “—Antidilution Adjustments” below.

		We shall, or shall cause the Calculation Agent to, (i) provide written notice to the Trustee and to The Depository Trust Company, which we refer to as DTC, of the amount of cash to be delivered with respect to the Stated Principal Amount, on or prior to 10:30 a.m. on the Trading Day preceding the Maturity Date (but if such Trading Day is not a Business Day, prior to the close of business on the Business Day preceding the Maturity Date), and (ii) deliver the aggregate cash amount due with respect to the PLUS to the Trustee for delivery to DTC, as holder of the PLUS, on the Maturity Date. We expect such amount of cash will be distributed to investors on the Maturity Date in accordance with the standard rules and procedures of DTC and its direct and indirect participants. See “—Book Entry Note or Certificated

PS-12

		Note” below, and see “The Depositary” in the accompanying prospectus supplement.

Maximum Payment at Maturity		$11.85

Leveraged Upside Payment		The product of (i) $10 and (ii) the Leverage Factor and (iii) the Share Percent Increase.

Leverage Factor		200%

Share Percent Increase		A fraction, the numerator of which is the Final Share Price minus the Initial Share Price and the denominator of which is the Initial Share Price.

Share Performance Factor		A fraction, the numerator of which is the Final Share Price and the denominator of which is the Initial Share Price.

Initial Share Price		$82.76, the Closing Price of one Underlying Share on the Pricing Date.

Closing Price		Subject to the provisions set out under “—Discontinuance of the Underlying Shares and/or Nasdaq Biotechnology Index; Alteration of Method of Calculation” below, the Closing Price for the Underlying Shares (or one unit of any other security for which a Closing Price must be determined) on any Trading Day means:

		(i) if the Underlying Shares (or any such other security) are listed or admitted to trading on a national securities exchange (other than The NASDAQ Stock Market LLC (the “NASDAQ”)), the last reported sale price, regular way, of the principal trading session on such day on the principal national securities exchange registered under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on which the Underlying Shares (or any such other security) are listed or admitted to trading,

		(ii) if the Underlying Shares (or any such other security) are securities of the NASDAQ, the official closing price published by the NASDAQ on such day, or

		(iii) if the Underlying Shares (or any such other security) are not listed or admitted to trading on any national securities exchange but are included in the OTC Bulletin Board Service (the “OTC Bulletin Board”) operated by the National Association of Securities Dealers, Inc. (the “NASD”), the last reported sale price of the principal trading session on the OTC Bulletin Board on such day.

		If the Underlying Shares (or any such other security) are listed or admitted to trading on any national securities exchange but the last reported sale price or the official closing price published by the NASDAQ, as applicable, is not available pursuant to the preceding sentence, then the Closing Price for one Underlying Share (or one unit of any such other security) on any Trading Day will mean the last reported sale price of the principal trading session on the over-the-counter market as reported on the NASDAQ or the OTC Bulletin Board on such day. If a Market

PS-13

		Disruption Event (as defined below) occurs with respect to the Underlying Shares (or any such other security) or the last reported sale price or the official closing price published by the NASDAQ, as applicable, for the Underlying Shares (or any such other security) is not available pursuant to either of the two preceding sentences, then the Closing Price for any Trading Day will be the mean, as determined by the Calculation Agent, of the bid prices for the Underlying Shares (or any such other security) for such Trading Day obtained from as many recognized dealers in such security, but not exceeding three, as will make such bid prices available to the Calculation Agent. Bids of Morgan Stanley & Co. Incorporated and its successors (“MS & Co.”) or any of its affiliates may be included in the calculation of such mean, but only to the extent that any such bid is the highest of the bids obtained. The term “OTC Bulletin Board Service” will include any successor service thereto. See “—Discontinuance of the Underlying Shares and/or Nasdaq Biotechnology Index; Alteration of Method of Calculation” below.

Final Share Price		The Closing Price of one Underlying Share times the Adjustment Factor, each as determined by the Calculation Agent on the Valuation Date.

Adjustment Factor		1.0, subject to adjustment in the event of certain events affecting the Underlying Shares. See “—Antidilution Adjustments” below.

Valuation Date		December 18, 2008, subject to postponement as described in the following paragraph.

		If a Market Disruption Event occurs on the scheduled Valuation Date, or if such Valuation Date is not a Trading Day, the Final Share Price will be determined on the immediately succeeding Trading Day on which no Market Disruption Event shall have occurred; provided that the Final Share Price will not be determined on a date later than the fifth scheduled Trading Day after the scheduled Valuation Date and if such date is not a Trading Day or if there is a Market Disruption Event on such date, the Calculation Agent will determine the Final Share Price as the mean, as determined by the Calculation Agent, of the bid prices for the Underlying Shares for such date obtained from as many recognized dealers in such security, but not exceeding three, as will make such bid prices available to the Calculation Agent. Bids of MS & Co. or any of its affiliates may be included in the calculation of such mean, but only to the extent that any such bid is the highest of the bids obtained.

Trading Day		A day, as determined by the Calculation Agent, on which trading is generally conducted on the New York Stock Exchange LLC (“NYSE”), the American Stock Exchange LLC, The NASDAQ Stock Market LLC, the Chicago Mercantile Exchange and the Chicago Board of Options Exchange and in the over-the-counter market for equity securities in the United States.

Book Entry Note or Certificated Note		Book Entry. The PLUS will be issued in the form of one or more fully registered global securities which will be deposited with, or on behalf of, DTC and will be registered in the name of a nominee

PS-14

		of DTC. DTC’s nominee will be the only registered holder of the PLUS. Your beneficial interest in the PLUS will be evidenced solely by entries on the books of the securities intermediary acting on your behalf as a direct or indirect participant in DTC. In this pricing supplement, all references to payments or notices to you will mean payments or notices to DTC, as the registered holder of the PLUS, for distribution to participants in accordance with DTC’s procedures. For more information regarding DTC and book entry notes, please read “The Depositary” in the accompanying prospectus supplement and “Form of Securities—Global Securities—Registered Global Securities” in the accompanying prospectus.

Senior Note or Subordinated Note		Senior

Trustee		The Bank of New York, a New York banking corporation (as successor Trustee to JPMorgan Chase Bank, N.A.)

Agent		MS & Co.

Calculation Agent		MS & Co.

		All determinations made by the Calculation Agent will be at the sole discretion of the Calculation Agent and will, in the absence of manifest error, be conclusive for all purposes and binding on you, the Trustee and us.

		All calculations with respect to the Payment at Maturity, if any, will be rounded to the nearest one hundred-thousandth, with five one-millionths rounded upward (e.g., .876545 would be rounded to .87655); all dollar amounts related to determination of the amount of cash payable per PLUS will be rounded to the nearest ten-thousandth, with five one hundred-thousandths rounded upward (e.g., .76545 would be rounded up to .7655); and all dollar amounts paid on the aggregate number of PLUS will be rounded to the nearest cent, with one-half cent rounded upward.

		Because the Calculation Agent is our subsidiary, the economic interests of the Calculation Agent and its affiliates may be adverse to your interests as an investor in the PLUS, including with respect to certain determinations and judgments that the Calculation Agent must make in determining the Initial Share Price, the Final Share Price or whether a Market Disruption Event has occurred. See “—Market Disruption Event,” “—Antidilution Adjustments” and “—Discontinuance of the Underlying Shares and/or Nasdaq Biotechnology Index; Alteration of Method of Calculation” below. MS & Co. is obligated to carry out its duties and functions as Calculation Agent in good faith and using its reasonable judgment.

Market Disruption Event		Market Disruption Event means, with respect to the Underlying Shares:

		(i) the occurrence or existence of a suspension, absence or material limitation of trading of the Underlying Shares on the primary market for the Underlying Shares for more

PS-15

		than two hours of trading or during the one-half hour period preceding the close of the principal trading session in such market; or a breakdown or failure in the price and trade reporting systems of the primary market for the Underlying Shares as a result of which the reported trading prices for the Underlying Shares during the last one-half hour preceding the close of the principal trading session in such market are materially inaccurate; or the suspension, absence or material limitation of trading on the primary market for trading in futures or options contracts related to the Underlying Shares, if available, during the one-half hour period preceding the close of the principal trading session in the applicable market, in each case as determined by the Calculation Agent in its sole discretion; or

		(ii) the occurrence or existence of a suspension, absence or material limitation of trading of stocks then constituting 20 percent or more of the value of the Nasdaq Biotechnology Index on the Relevant Exchanges for such securities for more than two hours of trading or during the one-half hour period preceding the close of the principal trading session on such Relevant Exchanges; or

		(iii) the suspension, material limitation or absence of trading on any major U.S. securities market for trading in futures or options contracts related to the Nasdaq Biotechnology Index or the Underlying Shares for more than two hours of trading or during the one-half hour period preceding the close of the principal trading session on such market, in each case as determined by the Calculation Agent in its sole discretion; and

		(iv) a determination by the Calculation Agent in its sole discretion that any event described in clauses (i), (ii) or (iii) above materially interfered with our ability or the ability of any of our affiliates to unwind or adjust all or a material portion of the hedge position with respect to the PLUS.

		For the purpose of determining whether a Market Disruption Event exists at any time, if trading in a security included in the Nasdaq Biotechnology Index is materially suspended or materially limited at that time, then the relevant percentage contribution of that security to the level of the Nasdaq Biotechnology Index shall be based on a comparison of (x) the portion of the level of the Nasdaq Biotechnology Index attributable to that security relative to (y) the overall level of the Nasdaq Biotechnology Index, in each case immediately before that suspension or limitation.

		For the purpose of determining whether a Market Disruption Event has occurred: (1) a limitation on the hours or number of days of trading will not constitute a Market Disruption Event if it results from an announced change in the regular business hours of the Relevant Exchange or market, (2) a decision to permanently

PS-16

		discontinue trading in the relevant futures or options contract or any exchange-traded fund, including the Underlying Shares, will not constitute a Market Disruption Event, (3) limitations pursuant to the rules of any Relevant Exchange or market similar to NYSE Rule 80A (or any applicable rule or regulation enacted or promulgated by any other self-regulatory organization or any government agency of scope similar to NYSE Rule 80A as determined by the Calculation Agent) on trading during significant market fluctuations will constitute a suspension, absence or material limitation of trading, (4) a suspension of trading in futures or options contracts on the Nasdaq Biotechnology Index or the Underlying Shares by the primary securities market trading in such contracts by reason of (a) a price change exceeding limits set by such securities exchange or market, (b) an imbalance of orders relating to such contracts or (c) a disparity in bid and ask quotes relating to such contracts will constitute a suspension, absence or material limitation of trading in futures or options contracts related to the Nasdaq Biotechnology Index or the Underlying Shares and (5) a “suspension, absence or material limitation of trading” on any Relevant Exchange or on the primary market on which futures or options contracts related to the Nasdaq Biotechnology Index or the Underlying Shares are traded will not include any time when such securities market is itself closed for trading under ordinary circumstances.

Relevant Exchange		Relevant Exchange means the primary exchange or market of trading for any security (or any combination thereof) then included in the Nasdaq Biotechnology Index or any Successor Index (as described below).

Antidilution Adjustments		If the Underlying Shares are subject to a stock split or reverse stock split, then once such split has become effective, the Adjustment Factor will be adjusted to equal the product of the prior Adjustment Factor and the number of shares issued in such stock split or reverse stock split with respect to one Underlying Share.

		No adjustment to the Adjustment Factor pursuant to the paragraph above will be required unless such adjustment would require a change of at least 0.1% in the amount being adjusted as then in effect. Any number so adjusted will be rounded to the nearest one hundred-thousandth with five one-millionths being rounded upward.

Index Publisher		The Nasdaq Stock Market, Inc. or any successor thereof

Discontinuance of the Underlying
Shares and/or Nasdaq Biotechnology Index; Alteration of Method of Calculation		If the iShares^® Nasdaq Biotechnology Index Fund is liquidated or otherwise terminated (a “Liquidation Event”), the Closing Price of the Underlying Shares on the Valuation Date will be determined by the Calculation Agent and will be deemed to equal the product of (i) the closing value of the Nasdaq Biotechnology Index (or any Successor Index, as described below) on the Valuation Date (taking into account any material changes in the method of calculating the Nasdaq Biotechnology Index following such

PS-17

		Liquidation Event) times (ii) a fraction, the numerator of which is the Closing Price of the Underlying Shares and the denominator of which is the closing value of the Nasdaq Biotechnology Index (or any Successor Index, as described below), each determined as of the last day prior to the occurrence of the Liquidation Event on which a Closing Price of the Underlying Shares was available.

		If the Index Publisher discontinues publication of the Nasdaq Biotechnology Index and the Index Publisher or another entity (including MS & Co.) publishes a successor or substitute index that MS & Co., as the Calculation Agent, determines, in its sole discretion, to be comparable to the discontinued Nasdaq Biotechnology Index (such index being referred to herein as a “Successor Index”), then any subsequent Closing Price following a Liquidation Event will be determined by reference to the published value of such Successor Index at the regular weekday close of trading on the Trading Day on which any Closing Price is to be determined.

		Upon any selection by the Calculation Agent of a Successor Index, the Calculation Agent will cause written notice thereof to be furnished to the Trustee, to us and to DTC, as holder of the PLUS, within three Trading Days of such selection. We expect that such notice will be passed on to you, as a beneficial owner of the PLUS, in accordance with the standard rules and procedures of DTC and its direct and indirect participants.

		If the Index Publisher discontinues publication of the Nasdaq Biotechnology Index prior to, and such discontinuance is continuing on, the Valuation Date following a Liquidation Event and MS & Co., as the Calculation Agent, determines, in its sole discretion, that no Successor Index is available at such time, then the Calculation Agent will determine the Closing Price for such date. The Closing Price will be computed by the Calculation Agent in accordance with the formula for calculating the Nasdaq Biotechnology Index last in effect prior to such discontinuance, using the closing price (or, if trading in the relevant securities has been materially suspended or materially limited, its good faith estimate of the closing price that would have prevailed but for such suspension or limitation) at the close of the principal trading session of the Relevant Exchange on such date of each security most recently composing the Nasdaq Biotechnology Index without any rebalancing or substitution of such securities following such discontinuance. Notwithstanding these alternative arrangements, discontinuance of the publication of the Nasdaq Biotechnology Index may adversely affect the value of the PLUS.

Alternate Exchange Calculation
in Case of an Event of Default		In case an event of default with respect to the PLUS shall have occurred and be continuing, the amount declared due and payable per PLUS upon any acceleration of the PLUS (an “Event of Default Acceleration”) shall be determined by the Calculation Agent and shall be an amount in cash equal to the Payment at Maturity calculated as if the product of the Closing Price as of the date of such acceleration and the Adjustment Factor as of such date were the Final Share Price.

PS-18

		If the maturity of the PLUS is accelerated because of an event of default as described above, we shall, or shall cause the Calculation Agent to, provide written notice to the Trustee at its New York office, on which notice the Trustee may conclusively rely, and to DTC of the cash amount due with respect to the PLUS as promptly as possible and in no event later than two Business Days after the date of acceleration.

The iShares^® Nasdaq Biotechnology
Index Fund; Public Information		iShares, Inc. (the “Company”) is a registered investment company that consists of numerous separate investment portfolios, including the iShares^® Nasdaq Biotechnology Index Fund. This fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Nasdaq Biotechnology Index. Information provided to or filed with the Commission by the Company pursuant to the Securities Act of 1933 and the Investment Company Act of 1940 can be located by reference to Commission file numbers 033-97598 and 811-09102, respectively, through the Commission’s website at http://www.sec.gov. In addition, information may be obtained from other sources including, but not limited to, press releases, newspaper articles and other publicly disseminated documents. We make no representation or warranty as to the accuracy or completeness of such information.

		This pricing supplement relates only to the PLUS offered hereby and does not relate to the Underlying Shares. We have derived all disclosures contained in this pricing supplement regarding the Company from the publicly available documents described in the preceding paragraph. In connection with the offering of the PLUS, neither we nor the Agent has participated in the preparation of such documents or made any due diligence inquiry with respect to the Company. Neither we nor the Agent makes any representation that such publicly available documents or any other publicly available information regarding the Company is accurate or complete. Furthermore, we cannot give any assurance that all events occurring prior to the date hereof (including events that would affect the accuracy or completeness of the publicly available documents described in the preceding paragraph) that would affect the trading price of the Underlying Shares (and therefore the price of the Underlying Shares at the time we priced the PLUS) have been publicly disclosed. Subsequent disclosure of any such events or the disclosure of or failure to disclose material future events concerning the Company could affect the value received at maturity with respect to the PLUS and therefore the trading prices of the PLUS.

		Neither we nor any of our affiliates makes any representation to you as to the performance of the Underlying Shares.

		We and/or our affiliates may presently or from time to time engage in business with the Company. In the course of such business, we and/or our affiliates may acquire non-public information with respect to the Company, and neither we nor any of our affiliates undertakes to disclose any such information to

PS-19

		you. In addition, one or more of our affiliates may publish research reports with respect to the Underlying Shares. The statements in the preceding two sentences are not intended to affect the rights of investors in the PLUS under the securities laws. As a prospective purchaser of the PLUS, you should undertake an independent investigation of the Company as in your judgment is appropriate to make an informed decision with respect to an investment in the Underlying Shares.

		iShares^® is a registered trademark of Barclays Global Investors, N.A. (“BGI”). The PLUS are not sponsored, endorsed, sold, or promoted by BGI. BGI makes no representations or warranties to the owners of the PLUS or any member of the public regarding the advisability of investing in the PLUS. BGI has no obligation or liability in connection with the operation, marketing, trading or sale of the PLUS.

The Nasdaq Biotechnology Index		We have derived all information contained in this prospectus supplement regarding the Nasdaq Biotechnology Index, including, without limitation, its make-up, method of calculation and changes in its components, from publicly available information. Such information reflects the policies of, and is subject to change by, Nasdaq. The Nasdaq Biotechnology Index was developed by, and is determined, calculated and maintained by Nasdaq without regard to the PLUS.

		The Nasdaq Biotechnology Index includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. On November 1, 1993, the Nasdaq Biotechnology Index began with a base of 200.00. To be eligible for inclusion in the Nasdaq Biotechnology Index, a security must be listed on The Nasdaq Stock Market and meet the following criteria:

		· the security’s U.S. listing must be exclusively on the NASDAQ National Market (unless the security was dually listed on another U.S. market prior to January 1, 2004 and has continuously maintained such listing);
		· the issuer of the security must be classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals;
		· the security may not be issued by an issuer currently in bankruptcy proceedings;
		· the security must have a market capitalization of at least $200 million;
		· the security must have an average daily trading volume of at least 100,000 shares;

PS-20

		· the issuer of the security may not have entered into a definitive agreement or other arrangement which would likely result in the security no longer being eligible for inclusion in the Nasdaq Biotechnology Index;
		· the issuer of the security may not have annual financial statements with an audit opinion that is currently withdrawn; and
		· the issuer of the security must have "seasoned" on NASDAQ or another recognized market for at least 6 months; in the case of spin-offs, the operating history of the spin-off will be considered.
		Semi-annual Ranking Review

		The securities composing the Nasdaq Biotechnology Index are evaluated semi-annually. Securities currently within the Nasdaq Biotechnology Index must meet the maintenance criteria of $100 million in market capitalization and 50,000 shares average daily trading volume. The securities included in the Nasdaq Biotechnology Index not meeting the maintenance criteria are retained in the Nasdaq Biotechnology Index provided that such security met the maintenance criteria in the previous semi-annual ranking. Securities not meeting the maintenance criteria for two consecutive rankings are removed. Index-eligible securities not currently in the Nasdaq Biotechnology Index are added. Changes will occur after the close of trading on the third Friday in May and November. The data used in the ranking includes end of March and September Nasdaq market data and is updated for total shares outstanding submitted in a publicly filed SEC document via EDGAR through the end of April and October.

		In addition to the Ranking Review, the securities in the Nasdaq Biotechnology Index are monitored every day by Nasdaq with respect to changes in total shares outstanding arising from secondary offerings, stock repurchases, conversions, or other corporate actions. Nasdaq has adopted the following weight adjustment procedures with respect to such changes. Changes in total shares outstanding arising from stock splits, stock dividends, or spin-offs are generally made to the Nasdaq Biotechnology Index on the evening prior to the effective date of such corporate action. If the change in total shares outstanding arising from other corporate actions is greater than or equal to 5.0%, the change will be made as soon as practicable, normally within ten (10) days of such action. Otherwise, if the change in total shares outstanding is less than 5.0%, then all such changes are accumulated and made effective at one time on a quarterly basis after the close of trading on the third Friday in each of March, June, September, and December. In either case, the index share weights for such securities included in the Nasdaq Biotechnology Index are adjusted by the same percentage amount by which the total shares outstanding have changed in such securities included in the Nasdaq Biotechnology Index.

PS-21

		You can find a list of the companies whose common stocks are currently included in the Nasdaq Biotechnology Index on the Nasdaq website at http://dynamic.nasdaq.com/dynamic/ nasdaqbiotech_activity.stm.

Historical Information		The following table sets forth the published high and low Closing Prices, as well as end-of-quarter Closing Prices, of the Underlying Shares for each quarter in the period from January 1, 2002 through September 21, 2007. The Closing Price on September 21, 2007 was $82.76. We obtained the information in the table below from Bloomberg Financial Markets, without independent verification. The historical prices of the Underlying Shares should not be taken as an indication of future performance, and no assurance can be given as to the price of the Underlying Shares on the Valuation Date. The price of the Underlying Shares may decrease so that you will receive a Payment at Maturity that is less than the principal amount of the PLUS. We cannot give you any assurance that the price of the Underlying Shares will increase so that at maturity you will receive a payment in excess of the principal amount of the PLUS. Because of the Leverage Factor, the Maximum Payment at Maturity will be reached at a Final Share Price of 109.25% of the Initial Share Price. In addition, you will not share in increases in the Final Share Price above 118.5% of the Initial Share Price. Because your return is linked to the price of the Underlying Shares on the Valuation Date, there is no guaranteed return of principal.

		If the Final Share Price is less than the Initial Share Price, you will lose money on your investment.

Use of Proceeds and Hedging		The net proceeds we receive from the sale of the PLUS will be used for general corporate purposes and, in part, in connection with hedging our obligations under the PLUS through one or more of our subsidiaries. The Issue Price of the PLUS includes the Agent’s Commissions (as shown on the cover page of this pricing supplement) paid with respect to the PLUS and the cost of hedging our obligations under the PLUS. The cost of hedging includes the projected profit that our subsidiaries expect to realize in consideration for assuming the risks inherent in managing the hedging transactions. Since hedging our obligations entails risk and may be influenced by market forces beyond our or our subsidiaries’ control, such hedging may result in a profit that is more or less than initially projected, or could result in a loss. See also “Use of Proceeds” in the accompanying prospectus.

		On or prior to the day we priced the PLUS for initial sale to the public, we, through our subsidiaries or others, hedged our anticipated exposure in connection with the PLUS by taking positions in the Underlying Shares or in options contracts on the Underlying Shares. Such purchase activity could potentially have increased the price of the Underlying Shares, and therefore effectively increased the price at which the Underlying Shares must close before you would receive at maturity a payment that exceeds the principal amount of the PLUS. In addition, through our subsidiaries, we are likely to modify our hedge position throughout the life of the PLUS by purchasing and selling the

PS-23

		Underlying Shares, options contracts relating to the Underlying Shares or any other available securities or instruments that we may wish to use in connection with such hedging activities, including by selling any such securities or instruments on the Valuation Date. We cannot give any assurance that our hedging activity will not affect the price of the Underlying Shares and, therefore, adversely affect the value of the PLUS or the payment you will receive at maturity.

Supplemental Information Concerning
Plan of Distribution		Under the terms and subject to the conditions contained in the U.S. distribution agreement referred to in the prospectus supplement under “Plan of Distribution,” the Agent, acting as principal for its own account, has agreed to purchase, and we have agreed to sell, the principal amount of PLUS set forth on the cover of this pricing supplement; provided that the price to public and the agent’s commissions for the purchase by any single investor of between $1,000,000 and $2,999,999 principal amount of PLUS will be $9.975 per PLUS and $0.125 per PLUS, respectively, for the purchase by any single investor of between $3,000,000 and $4,999,999 principal amount of PLUS will be $9.9625 per PLUS and $0.1125 per PLUS, respectively, and for the purchase by any single investor of $5,000,000 or more principal amount of PLUS will be $9.95 per PLUS and $0.10 per PLUS, respectively. The Agent proposes initially to offer the PLUS directly to the public at the public offering price set forth on the cover page of this pricing supplement. The Agent may allow a concession not in excess of $0.15 per PLUS to other dealers, which may include Morgan Stanley & Co. International plc and Bank Morgan Stanley AG; provided that, concessions allowed to dealers in connection with the offering may be reclaimed by the Agent if, within 30 days of the offering, the Agent repurchases PLUS distributed by such dealers. After the initial offering of the PLUS, the Agent may vary the offering price and other selling terms from time to time.

		We expect to deliver the PLUS against payment therefor in New York, New York on September 28, 2007, which will be the fifth scheduled Business Day following the date of this pricing supplement and of the pricing of the PLUS.

		In order to facilitate the offering of the PLUS, the Agent may engage in transactions that stabilize, maintain or otherwise affect the price of the PLUS or the price of the Underlying Shares. Specifically, the Agent may sell more PLUS than it is obligated to purchase in connection with the offering or may sell Underlying Shares or individual stocks underlying the Nasdaq Biotechnology Index it does not own, creating a naked short position in the PLUS, the Underlying Shares or the individual stocks underlying the Nasdaq Biotechnology Index, respectively, for its own account. The Agent must close out any naked short position by purchasing the PLUS, Underlying Shares or the individual stocks underlying the Nasdaq Biotechnology Index in the open market. A naked short position is more likely to be created if the Agent is concerned that there may be downward pressure on the price of the PLUS, the Underlying Shares or the individual stocks

PS-24

		underlying the Nasdaq Biotechnology Index in the open market to stabilize the price of the PLUS. Any of these activities may raise or maintain the market price of the PLUS above independent market prices or prevent or retard a decline in the market price of the PLUS. The Agent is not required to engage in these activities, and may end any of these activities at any time. An affiliate of the Agent has entered into a hedging transaction with us in connection with this offering of PLUS. See “—Use of Proceeds and Hedging” above.

		General

		No action has been or will be taken by us, the Agent or any dealer that would permit a public offering of the PLUS or possession or distribution of this pricing supplement or the accompanying prospectus supplement or prospectus in any jurisdiction, other than the United States, where action for that purpose is required. No offers, sales or deliveries of the PLUS, or distribution of this pricing supplement or the accompanying prospectus supplement or prospectus or any other offering material relating to the PLUS, may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and will not impose any obligations on us, the Agent or any dealer.

		The Agent has represented and agreed, and each dealer through which we may offer the PLUS has represented and agreed, that it (i) will comply with all applicable laws and regulations in force in each non-U.S. jurisdiction in which it purchases, offers, sells or delivers the PLUS or possesses or distributes this pricing supplement and the accompanying prospectus supplement and prospectus and (ii) will obtain any consent, approval or permission required by it for the purchase, offer or sale by it of the PLUS under the laws and regulations in force in each non-U.S. jurisdiction to which it is subject or in which it makes purchases, offers or sales of the PLUS. We shall not have responsibility for the Agent’s or any dealer’s compliance with the applicable laws and regulations or obtaining any required consent, approval or permission.

		Brazil

		The PLUS have not been and will not be registered with the Comissão de Valores Mobiliários (The Brazilian Securities Commission). The PLUS may not be offered or sold in the Federative Republic of Brazil except in circumstances which do not constitute a public offering or distribution under Brazilian laws and regulations.

PS-25

		Chile

		The PLUS have not been registered with the Superintendencia de Valores y Seguros in Chile and may not be offered or sold publicly in Chile. No offer, sales or deliveries of the PLUS or distribution of this pricing supplement or the accompanying prospectus supplement or prospectus, may be made in or from Chile except in circumstances which will result in compliance with any applicable Chilean laws and regulations.

		Hong Kong

		No action has been taken to permit an offering of the PLUS to the public in Hong Kong as the PLUS have not been authorized by the Securities and Futures Commission of Hong Kong and, accordingly, no advertisement, invitation or document relating to the PLUS, whether in Hong Kong or elsewhere, shall be issued, circulated or distributed which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong other than (i) with respect to the PLUS which are or are intended to be disposed of only to persons outside Hong Kong or only to professional investors within the meaning of the Securities and Futures Ordinance (Cap. 571) of Hong Kong (“SFO”) and any rules made thereunder or (ii) in circumstances that do not constitute an invitation to the public for the purposes of the SFO.

		Mexico

		The PLUS have not been registered with the National Registry of Securities maintained by the Mexican National Banking and Securities Commission and may not be offered or sold publicly in Mexico. This pricing supplement and the accompanying prospectus supplement and prospectus may not be publicly distributed in Mexico.

		Singapore

		The Agent and each dealer represent and agree that they will not offer or sell the PLUS nor make the PLUS the subject of an invitation for subscription or purchase, nor will they circulate or distribute this pricing supplement or the accompanying prospectus supplement or prospectus or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the PLUS, whether directly or indirectly, to persons in Singapore other than:

		(a) an institutional investor (as defined in section 4A of the Securities and Futures Act (Chapter 289 of Singapore (the “SFA”));

		(b) an accredited investor (as defined in section 4A of the SFA), and in accordance with the conditions, specified in Section 275 of the SFA;

		(c) a person who acquires the PLUS for an aggregate consideration of not less than Singapore dollars Two Hundred

PS-26

		Thousand (S$200,000) (or its equivalent in a foreign currency) for each transaction, whether such amount is paid for in cash, by exchange of shares or other assets, unless otherwise permitted by law; or

		(d) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.

ERISA Matters for Pension Plans and
Insurance Companies		Each fiduciary of a pension, profit-sharing or other employee benefit plan subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”) (a “Plan”), should consider the fiduciary standards of ERISA in the context of the Plan’s particular circumstances before authorizing an investment in the PLUS. Accordingly, among other factors, the fiduciary should consider whether the investment would satisfy the prudence and diversification requirements of ERISA and would be consistent with the documents and instruments governing the Plan.

		In addition, we and certain of our subsidiaries and affiliates, including MS & Co. may be considered a “party in interest” within the meaning of ERISA, or a “disqualified person” within the meaning of the Internal Revenue Code of 1986, as amended (the “Code”), with respect to many Plans, as well as many individual retirement accounts and Keogh plans (also “Plans”). Prohibited transactions within the meaning of ERISA or the Code would likely arise, for example, if the PLUS are acquired by or with the assets of a Plan with respect to which MS & Co. or any of its affiliates is a service provider or other party in interest, unless the PLUS are acquired pursuant to an exemption from the “prohibited transaction” rules. A violation of these “prohibited transaction” rules could result in an excise tax or other liabilities under ERISA and/or Section 4975 of the Code for such persons, unless exemptive relief is available under an applicable statutory or administrative exemption.

		The U.S. Department of Labor has issued five prohibited transaction class exemptions (“PTCEs”) that may provide exemptive relief for direct or indirect prohibited transactions resulting from the purchase or holding of the PLUS. Those class exemptions are PTCE 96-23 (for certain transactions determined by in-house asset managers), PTCE 95-60 (for certain transactions involving insurance company general accounts), PTCE 91-38 (for certain transactions involving bank collective investment funds), PTCE 90-1 (for certain transactions involving insurance company separate accounts) and PTCE 84-14 (for certain transactions determined by independent qualified asset managers). In addition, ERISA Section 408(b)(17) provides an exemption for the purchase and sale of securities and related lending transactions, provided that neither the issuer of the securities nor any of its affiliates have or exercise any discretionary authority or control or render any investment advice with respect to the assets of any Plan involved in the transaction, and provided further that the Plan pays no more than “adequate consideration” (to be defined in regulations to be issued by the Secretary of the Department of

PS-27

		Labor) in connection with the transaction (the so-called “service provider” exemption).

		Because we may be considered a party in interest with respect to many Plans, the PLUS may not be purchased, held or disposed of by any Plan, any entity whose underlying assets include “plan assets” by reason of any Plan’s investment in the entity (a “Plan Asset Entity”) or any person investing “plan assets” of any Plan, unless such purchase, holding or disposition is eligible for exemptive relief, including relief available under PTCEs 96-23, 95-60, 91-38, 90-1, 84-14 or the service provider exemption or such purchase, holding or disposition is otherwise not prohibited. Any purchaser, including any fiduciary purchasing on behalf of a Plan, transferee or holder of the PLUS will be deemed to have represented, in its corporate and its fiduciary capacity, by its purchase and holding of the PLUS that either (a) it is not a Plan or a Plan Asset Entity and is not purchasing such PLUS on behalf of or with “plan assets” of any Plan, or with any assets of a governmental or church plan that is subject to any federal, state or local law that is substantially similar to the provisions of Section 406 of ERISA of Section 4975 of the Code or (b) its purchase, holding and disposition are eligible for exemptive relief or such purchase, holding and disposition are not prohibited by ERISA or Section 4975 of the Code (or in the case of a governmental or church plan, any substantially similar federal, state or local law).

		Under ERISA, assets of a Plan may include assets of certain commingled vehicles and entities in which the Plan has invested (including, in certain cases, the general account of an insurance company). Accordingly, commingled vehicles and entities which include assets of a Plan must ensure that one of the foregoing exemptions is available. Due to the complexity of these rules and the penalties that may be imposed upon persons involved in non-exempt prohibited transactions, it is particularly important that fiduciaries or other persons considering purchasing the PLUS on behalf of or with “plan assets” of any Plan consult with their counsel regarding the availability of exemptive relief under any available exemptions, such as PTCEs 96-23, 95-60, 91-38, 90-1 or 84-14 or the service provider exemption.

		Purchasers of the PLUS have exclusive responsibility for ensuring that their purchase, holding and disposition of the PLUS do not violate the prohibited transaction rules of ERISA or the Code or similar regulations applicable to governmental or church plans, as described above. The sale of any PLUS to any Plan investor is in no respect a representation by us or any of our affiliates or representatives that such an investment meets all relevant legal requirements with respect to investments by Plan investors generally or any particular Plan investor, or that such an investment is appropriate for Plan investors generally or any particular Plan investor.

PS-28

United States Federal Income Taxation		Prospective investors should note that the discussion under the section called “United States Federal Taxation” in the accompanying prospectus supplement does not apply to the PLUS issued under this pricing supplement and is superseded by the following discussion.

		The following are the material U.S. federal tax consequences of ownership and disposition of the PLUS.

		This discussion only applies to initial investors in the PLUS who:

		• purchase the PLUS at their “issue price”; and
		• will hold the PLUS as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the “Code”).

		This discussion does not describe all of the tax consequences that may be relevant to a holder in light of the holder’s particular circumstances or to holders subject to special rules, such as:

		• certain financial institutions;
		• insurance companies;
		• dealers in securities or foreign currencies;
		• investors holding the PLUS as part of a hedging transaction, “straddle,” conversion transaction or integrated transaction;
		• U.S. Holders, as defined below, whose functional currency is not the U.S. dollar;
		• partnerships or other entities classified as partnerships for U.S. federal income tax purposes;
		• regulated investment companies;
		• real estate investment trusts;
		• tax-exempt entities, including an “individual retirement account” or “Roth IRA” as defined in Section 408 or 408A of the Code, respectively;
		• persons subject to the alternative minimum tax;
		• nonresident alien individuals who have lost their U.S. citizenship or who have ceased to be taxed as U.S. resident aliens; or
		• Non-U.S. Holders, as defined below, for whom income or gain in respect of the PLUS is effectively connected with the conduct of a trade or business in the United States.

		As the law applicable to the U.S. federal income taxation of instruments such as the PLUS is technical and complex, the discussion below necessarily represents only a general summary. Moreover, the effect of any applicable state, local or foreign tax laws is not discussed.

		This discussion is based on the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, all as of the date hereof, changes to any of which subsequent to the date of this pricing supplement may affect the tax consequences described herein. Persons considering the purchase of the PLUS are urged to consult their tax advisors with regard to the application of the U.S. federal tax

PS-29

		laws to their particular situations, as well as any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction.

		General

		The PLUS should be treated as a single financial contract that is an “open transaction” for U.S. federal income tax purposes. Due to the absence of statutory, judicial or administrative authorities that directly address the characterization or treatment of the PLUS or instruments that are similar to the PLUS for U.S. federal income tax purposes, no assurance can be given that the IRS or the courts will agree with the characterization and tax treatment described herein. Accordingly, you are urged to consult your own tax advisors regarding all aspects of the U.S. federal tax consequences of an investment in the PLUS (including alternative characterizations of the PLUS) and with respect to any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction. Unless otherwise stated, the following discussion is based on the characterization and treatment of the PLUS described above.

		Tax Consequences to U.S. Holders

		As used herein, the term “U.S. Holder” means a beneficial owner of a PLUS that is, for U.S. federal income tax purposes:

		• a citizen or resident of the United States;
		• a corporation, or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States or any political subdivision thereof; or
		• an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.

		The term “U.S. Holder” also includes certain former citizens and residents of the United States.

		*Tax Treatment of the PLUS*

		Assuming the characterization and treatment of the PLUS as set forth above is respected, the following U.S. federal income tax consequences should result.

		Tax Treatment Prior to Maturity. A U.S. Holder should not be required to recognize taxable income over the term of the PLUS prior to maturity, other than pursuant to a sale or exchange as described below.

		Tax Basis. A U.S. Holder’s tax basis in the PLUS should equal the amount paid by the U.S. Holder to acquire the PLUS.

		Sale, Exchange or Settlement of the PLUS. Upon a sale or exchange of the PLUS, or upon settlement of the PLUS at

PS-30

		maturity, a U.S. Holder should generally recognize gain or loss equal to the difference between the amount realized on the sale, exchange or settlement and the U.S. Holder’s tax basis in the PLUS sold, exchanged, or settled. Subject to the discussion below concerning the potential application of the “constructive ownership” rule under Section 1260 of the Code, any capital gain or loss recognized upon the sale, exchange or settlement of a PLUS should be long-term capital gain or loss if the U.S. Holder has held the PLUS for more than one year at such time.

		Potential Application of the Constructive Ownership Rule. A “constructive ownership transaction” includes a contract under which an investor will receive payment equal to or credit for the future value of any equity interest in a regulated investment company (such as shares of the iShares Nasdaq Biotech Index Fund (the “Underlying Shares”)). Under the “constructive ownership” rule, if an investment in the PLUS is treated as a “constructive ownership transaction,” any long-term capital gain recognized by a U.S. Holder in respect of a PLUS will be recharacterized as ordinary income to the extent such gain exceeds the amount of “net underlying long-term capital gain” (as defined in Section 1260 of the Code) of the U.S. Holder, determined as if the U.S. Holder had acquired the Underlying Shares on the Original Issue Date and sold them on the date of sale, exchange or settlement of the PLUS at fair market value (the “Excess Gain”). In addition, an interest charge will also apply to any deemed underpayment of tax in respect of any Excess Gain to the extent such gain would have resulted in gross income inclusion for the U.S. Holder in taxable years prior to the taxable year of the sale, exchange or settlement of the PLUS (assuming such income accrued at a constant rate equal to the applicable federal rate as of the date of sale, exchange or settlement of the PLUS).

		Although the matter is not clear, there is a substantial risk that an investment in the PLUS will be treated as a “constructive ownership transaction.” If such treatment applies, it is not clear to what extent any long-term capital gain of a U.S. Holder in respect of the PLUS will be recharacterized as ordinary income. It is possible, for example, that the amount of the Excess Gain (if any) that would be recharacterized as ordinary income in respect of each PLUS will equal the excess of (i) any long-term capital gain recognized by the U.S. Holder in respect of the PLUS (which, subject to the maximum payment at maturity, reflects two times the percentage increase in the value of the Underlying Shares over the term of the PLUS) over (ii) the “net underlying long-term capital gain” such U.S. Holder would have had if such U.S. Holder had acquired an amount of the Underlying Shares at fair market value on the Original Issue Date for an amount equal to the “issue price” of the PLUS and sold such amount of Underlying Shares upon the date of sale, exchange or settlement of the PLUS at fair market value (which would reflect the percentage increase in the value of the Underlying Shares over the term of the PLUS). Accordingly, U.S. Holders should consult

PS-31

		their tax advisors regarding the potential application of the “constructive ownership” rule.

		*Possible Alternative Tax Treatments of an Investment in the PLUS*

		Due to the absence of authorities that directly address the proper characterization or treatment of the PLUS, no assurance can be given that the IRS will accept, or that a court will uphold, the characterization and treatment described above. In particular, the IRS could seek to analyze the U.S. federal income tax consequences of owning a PLUS under Treasury regulations governing contingent payment debt instruments (the “Contingent Debt Regulations”).

		If the IRS were successful in asserting that the Contingent Debt Regulations apply to the PLUS, the timing and character of income thereon would be significantly affected. Among other things, a U.S. Holder would be required to accrue original issue discount on the PLUS every year at a “comparable yield” determined at the time of their issuance. Furthermore, any gain realized by a U.S. Holder at maturity or upon a sale or other disposition of the PLUS would generally be treated as ordinary income, and any loss realized at maturity would be treated as ordinary loss to the extent of the U.S. Holder’s prior accruals of original issue discount, and as capital loss thereafter.

		Even if the Contingent Debt Regulations do not apply to the PLUS, other alternative federal income tax characterizations of the PLUS are also possible, which if applied could also affect the timing and character of the income or loss with respect to the PLUS. It is possible, for example, that a PLUS could be treated as a unit consisting of a loan and a forward contract, in which case a U.S. Holder would be required to accrue original issue discount as income on a current basis. Accordingly, prospective investors are urged to consult their own tax advisors regarding all aspects of the U.S. federal income tax consequences of an investment in the PLUS.

		*Backup Withholding and Information Reporting*

		Backup withholding may apply in respect of the amounts paid to a U.S. Holder, unless such U.S. Holder provides proof of an applicable exemption or a correct taxpayer identification number, or otherwise complies with applicable requirements of the backup withholding rules. The amounts withheld under the backup withholding rules are not an additional tax and may be refunded, or credited against the U.S. Holder’s U.S. federal income tax liability, provided that the required information is furnished to the IRS. In addition, information returns will be filed with the IRS in connection with payments on the PLUS and the proceeds from a sale or other disposition of the PLUS, unless the U.S. Holder provides proof of an applicable exemption from the information reporting rules.

PS-32

		Tax Consequences to Non-U.S. Holders

		This section only applies to you if you are a Non-U.S. Holder. As used herein, the term “Non-U.S. Holder” means a beneficial owner of a PLUS that is, for U.S. federal income tax purposes:

		• an individual who is classified as a nonresident alien;
		• a foreign corporation; or
		• a foreign trust or estate.

		“Non-U.S. Holder” does not include a holder who is an individual present in the United States for 183 days or more in the taxable year of disposition and who is not otherwise a resident of the United States for U.S. federal income tax purposes. Such a holder is urged to consult his or her own tax advisors regarding the U.S. federal income tax consequences of the sale, exchange or other disposition of a PLUS.

		*Tax Treatment upon Sale, Exchange or Settlement of the PLUS*

		In general. Assuming the characterization and treatment of the PLUS as set forth above is respected, a Non-U.S. Holder of the PLUS will not be subject to U.S. federal income or withholding tax in respect of amounts paid to the Non-U.S. Holder.

		If all or any portion of a PLUS were recharacterized as a debt instrument, any payment made to a Non-U.S. Holder with respect to the PLUS would not be subject to U.S. federal withholding tax, provided that:

		• the Non-U.S. Holder does not own, directly or by attribution, ten percent or more of the total combined voting power of all classes of our stock entitled to vote;

		• the Non-U.S. Holder is not a controlled foreign corporation related, directly or indirectly, to us through stock ownership;

		• the Non-U.S. Holder is not a bank receiving interest under section 881(c)(3)(A) of the Code; and

		• the certification requirement described below has been fulfilled with respect to the beneficial owner.

		Certification Requirement. The certification requirement referred to in the preceding paragraph will be fulfilled if the beneficial owner of a PLUS (or a financial institution holding the PLUS on behalf of the beneficial owner) furnishes to us an IRS Form W-8BEN, on which the beneficial owner certifies under penalties of perjury that it is not a U.S. person.

		*U.S. Federal Estate Tax*

		Individual Non-U.S. Holders and entities the property of which is potentially includible in such an individual’s gross estate for U.S. federal estate tax purposes (for example, a trust funded by such an

PS-33

		individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the PLUS are likely to be treated as U.S. situs property subject to U.S. federal estate tax. Prospective investors that are non-U.S. individuals, or are entities of the type described above, are urged to consult their own tax advisors regarding the U.S. federal estate tax consequences of investing in the PLUS.

		*Backup Withholding and Information Reporting*

		Information returns may be filed with the IRS in connection with the payment on the PLUS at maturity as well as in connection with the proceeds from a sale, exchange or other disposition. A Non-U.S. Holder may be subject to backup withholding in respect of amounts paid to the Non-U.S. Holder, unless such Non-U.S. Holder complies with certification procedures to establish that it is not a U.S. person for U.S. federal income tax purposes or otherwise establishes an exemption. The certification procedures described above under “―Tax Treatment upon Sale, Exchange or Settlement of the PLUS ― Certification Requirement” will satisfy the certification requirements necessary to avoid the backup withholding as well. The amount of any backup withholding from a payment to a Non-U.S. Holder will be allowed as a credit against the Non-U.S. Holder’s U.S. federal income tax liability and may entitle the Non-U.S. Holder to a refund, provided that the required information is furnished to the IRS.

*CALCULATION OF REGISTRATION FEE*

Title of Each Class of Securities Offered	Maximum Aggregate Offering Price	Amount of Registration Fee
Performance Leveraged Upside Securities due 2008	$3,800,000	$116.66

*PROSPECTUS Dated January 25, 2006*	*Pricing Supplement No. 366 to*
*Amendment No. 1 to PROSPECTUS SUPPLEMENT*	*Registration Statement No. 333-131266*
*Dated July 24, 2007*	*Dated September 21, 2007*
	*Rule 424(b)(2)*

	*Price to* *Public⁽¹⁾*	Agent’s Commissions⁽¹⁾⁽²⁾	*Proceeds to* *Company*
Per PLUS	$10.00	$0.15	$9.85
Total	$3,800,000	$57,000	$3,743,000

Each PLUS costs $10		We, Morgan Stanley, are offering Performance Leveraged Upside Securities^SM due December 20, 2008, Based on the Closing Price of Shares of the iShares^® Nasdaq Biotechnology Index Fund, which we refer to as the PLUS. The stated principal amount and issue price of each PLUS is $10.

		The original issue price of the PLUS includes the agent’s commissions paid with respect to the PLUS and the cost of hedging our obligations under the PLUS. The cost of hedging includes the projected profit that our subsidiaries may realize in consideration for assuming the risks inherent in managing the hedging transactions. The fact that the original issue price of the PLUS includes these commissions and hedging costs is expected to adversely affect the secondary market prices of the PLUS. See “Risk Factors—The inclusion of commissions and projected profit from hedging in the original issue price is likely to adversely affect secondary market prices” and “Description of PLUS—Use of Proceeds and Hedging.”

No guaranteed return of principal; no interest		Unlike ordinary debt securities, the PLUS do not pay interest and do not guarantee any return of principal at maturity. If the final share price is less than the initial share price, we will pay to you an amount in cash per PLUS that is less than the $10 stated principal amount of each PLUS by an amount proportionate to the decrease in the closing price of the underlying shares. The initial share price is $82.76, the closing price of one underlying share on the day we priced the PLUS for initial sale to the public, which we refer to as the pricing date. The final share price will be the closing price of one underlying share times the adjustment factor on December 18, 2008, which we refer to as the valuation date. The adjustment factor is initially set at 1.0 and is subject to change upon certain events affecting the underlying shares.

Payment at maturity based on the iShares^®Nasdaq Biotechnology Index Fund		At maturity, you will receive for each $10 stated principal amount of PLUS that you hold an amount in cash based upon the closing price of one underlying share on the valuation date, determined as follows: • If the final share price is greater than the initial share price, you will receive for each $10 stated principal amount of PLUS that you hold a payment at maturity equal to:
		$10 + leveraged upside payment,

		subject to a maximum payment at maturity of $11.85, or 118.5% of the $10 stated principal amount,

		final share price = the closing price of one underlying share times the adjustment factor, each as of the valuation date,

		initial share price = $82.76, the closing price of one underlying share on the pricing date,

		and

		adjustment factor = 1.0, subject to change upon certain events affecting the underlying shares.

		where,

		leveraged upside payment = $10 × leverage factor × share percent increase,

		leverage factor = 200%,

share percent increase	=	final share price − initial share price
		initial share price

		• If the final share price is less than or equal to the initial share price, you will receive for each $10 stated principal amount of PLUS that you hold a payment at maturity equal to:
		$10 × share performance factor

		where,

		Because the share performance factor will be less than or equal to 1.0, this payment will be less than or equal to $10.

		On PS-7, we have provided a graph titled “Hypothetical Payouts on the PLUS at Maturity,” which illustrates the performance of the PLUS at maturity over a range of hypothetical percentage changes in the closing price of the underlying shares. The graph does not show every situation that may occur.

		You can review the historical prices of the underlying shares in the section of this pricing supplement called “Description of PLUS—Historical Information.” The iShares^® Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Nasdaq Biotechnology Index.

The adjustment factor may be changed		During the life of the PLUS, our affiliate, Morgan Stanley & Co. Incorporated or its successors, which we refer to as MS & Co., acting as calculation agent, may make changes to the adjustment factor, initially set at 1.0, to reflect the occurrence of certain events relating to the underlying shares. You should read about these adjustments in the sections of this pricing supplement called “Risk Factors—The antidilution adjustments the calculation agent is required to make do not cover every event that could affect the underlying shares,” “Description of PLUS—Adjustment Factor” and “—Antidilution Adjustments.”

You have no shareholder rights		Investing in the PLUS is not equivalent to investing in the underlying shares or the stocks composing the Nasdaq Biotechnology Index. As an investor in the PLUS, you will not have voting rights or rights to receive dividends or other distributions or any other rights with respect to the underlying shares or the stocks composing the Nasdaq Biotechnology Index. In addition, you do not have the right to exchange your PLUS for underlying shares at any time.

Your return on the PLUS is limited by the maximum payment at maturity		The return investors realize on the PLUS is limited by the maximum payment at maturity. The maximum payment at maturity of each PLUS is $11.85, or 118.5% of the $10 stated principal amount. Although the leverage factor provides 200% exposure to any increase in the closing price of the underlying shares at maturity, because the payment at maturity will be limited to 118.5% of the $10 stated principal amount, the percentage exposure provided by the leverage factor is progressively reduced as the final share price exceeds 109.25% of the initial share price. See “Hypothetical Payouts on the PLUS at Maturity” on PS-7.

Postponement of maturity date		If a market disruption event occurs on the scheduled valuation date or the scheduled valuation date is not otherwise a trading day, the maturity date will be postponed until the second scheduled trading day following the valuation date as postponed.

The iShares^® Nasdaq Biotechnology Index Fund		The underlying shares are shares of the iShares^® Nasdaq Biotechnology Index Fund. The iShares^® Nasdaq Biotechnology Index Fund is an exchange-traded fund managed by iShares^®, Inc., a registered investment company. iShares^®, Inc. consists of numerous separate investment portfolios, including the Nasdaq Biotechnology Index Fund. The iShares^® Nasdaq Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Nasdaq Biotechnology Index. It is possible that this fund may not fully replicate or may in certain circumstances diverge significantly from the performance of the Nasdaq Biotechnology Index due to the temporary unavailability of certain securities in the secondary market, the performance of any derivative instruments contained in this fund or due to other circumstances.

The Nasdaq Biotechnology Index		The Nasdaq Biotechnology Index is calculated, published and disseminated by The Nasdaq Stock Market, Inc., which we refer to as Nasdaq, and is designed to measure performance of Nasdaq-listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals which also meet other eligibility criteria determined by Nasdaq. For further information regarding the Nasdaq Biotechnology Index, see “Description of PLUS—The Nasdaq Biotechnology Index.”

MS & Co. will be the Calculation Agent		We have appointed our affiliate, MS & Co., to act as calculation agent for The Bank of New York, a New York banking corporation (as successor trustee to JPMorgan Chase Bank, N.A.), the trustee for our senior notes. As calculation agent, MS & Co. determined the initial share price and will determine the final share price, the percentage change in the underlying shares from their initial share price to the final share price, the payment to you at maturity and whether a market disruption event has occurred.

		Because this is a summary, it does not contain all of the information that may be important to you. For a detailed description of the terms of the PLUS, you should read the “Description of PLUS” section in this pricing supplement. You should also read about some of the risks involved in investing in the PLUS in the section called “Risk Factors.” The tax treatment of investments in notes such as these differ from that of investments in ordinary debt securities. See the section of this pricing supplement called “Description of PLUS—United States Federal Income Taxation.” We urge you to consult with your investment, legal, tax, accounting and other advisors with regard to any proposed or actual investment in the PLUS.

How to reach us		You may contact your local Morgan Stanley branch office or our principal executive offices at 1585 Broadway, New York, New York 10036 (telephone number (212) 761-4000).

•	Stated principal amount per PLUS:	$10

•	Initial share price:	$82.76

•	Leverage factor:	200%

•	Maximum payment at maturity:	$11.85 (118.50% of the $10 stated principal amount)

PLUS do not pay interest or guarantee return of principal		The terms of the PLUS differ from those of ordinary debt securities in that we will not pay you interest on the PLUS or guarantee to pay you the principal amount of the PLUS at maturity. Instead, at maturity, you will receive for each $10 stated principal amount of PLUS that you hold an amount in cash based upon the final share price. If the final share price is greater than the initial share price, you will receive an amount in cash equal to $10 plus the leveraged upside payment, subject to a maximum payment at maturity of $11.85, or 118.5% of the $10 stated principal amount. If the final share price is *less than* the initial share price, you will lose money on your investment; you will receive an amount in cash that is less than the $10 stated principal amount of each PLUS by an amount proportionate to the decrease in the closing price of the underlying shares. See “Hypothetical Payouts on the PLUS at Maturity” on PS–7.

Your appreciation potential is limited		The appreciation potential of the PLUS is limited by the maximum payment at maturity of $11.85, or 118.5% of the $10 stated principal amount. As a result, you will not share in any appreciation of the underlying shares above 118.5% of the price of the underlying shares on the day we priced the PLUS for initial sale to the public. Although the leverage factor provides 200% exposure to any increase in the price of the underlying shares as of the valuation date, because the payment at maturity is limited to 118.5% of the $10 stated principal amount, the enhanced return provided by the leverage factor is progressively reduced as the final share price exceeds 109.25% of the initial share price. See “Hypothetical Payouts on the PLUS at Maturity” on PS–7.

The PLUS will not be listed		The PLUS will not be listed on any securities exchange. Therefore, there may be little or no secondary market for the PLUS. MS & Co. currently intends to act as a market maker for the PLUS but is not required to do so. Even if there is a secondary market, it may not provide enough liquidity to allow you to trade or sell the PLUS easily. Because we do not expect that other market makers will participate significantly in the secondary market for the PLUS, the price at which you may be able to trade your PLUS is likely to depend on the price, if any, at which MS & Co. is willing to transact. If, at any time, MS & Co. were to cease acting as a market maker, it is likely that there would be no secondary market for the PLUS. Because it is not possible to predict whether the market for the PLUS will be liquid or illiquid, you should be willing to hold your PLUS to maturity.

Market price of the PLUS may be influenced by many unpredictable factors		Several factors, many of which are beyond our control, will influence the value of the PLUS in the secondary market and the price at which MS & Co. may be willing to purchase or sell the PLUS in the secondary market. We expect that generally the trading price of the underlying shares on any day will affect the value of the PLUS more than any other single factor. Other factors that may influence the value of the PLUS include:

		• the volatility (frequency and magnitude of changes in price) of the underlying shares;
		• geopolitical conditions and economic, financial, political, regulatory or judicial events that affect the securities underlying the Nasdaq Biotechnology Index or

		stock markets generally, and which may affect the trading price of the underlying shares;

		• interest and yield rates in the market;
		• the dividend rate on the underlying shares;
		• the time remaining until the PLUS mature;
		• our creditworthiness; and
		• the occurrence of certain events affecting the underlying shares that may or may not require an adjustment to the adjustment factor.
		Some or all of these factors will influence the price you will receive if you sell your PLUS prior to maturity. For example, you may have to sell your PLUS at a substantial discount from the principal amount if the trading price of the underlying shares is at, below, or not sufficiently above the initial share price.

		You cannot predict the future performance of the underlying shares based on their historical performance. The price of the underlying shares may decrease so that you will receive at maturity a payment that is less than the principal amount of the PLUS by an amount proportionate to the decrease in the price of the underlying shares. In addition, there can be no assurance that the price of the underlying shares will increase so that you will receive at maturity an amount in excess of the principal amount of the PLUS. Nor can there be any assurance that the price of the underlying shares will not increase beyond 118.5% of the initial share price, in which case you will only receive the maximum payment at maturity. You will no longer share in the performance of the underlying shares at prices above 118.5% of the initial share price.

The inclusion of commissions and projected profit from hedging in the original issue price is likely to adversely affect secondary market prices		Assuming no change in market conditions or any other relevant factors, the price, if any, at which MS & Co. is willing to purchase PLUS in secondary market transactions will likely be lower than the original issue price, since the original issue price included, and secondary market prices are likely to exclude, commissions paid with respect to the PLUS, as well as the projected profit included in the cost of hedging our obligations under the PLUS. In addition, any such prices may differ from values determined by pricing models used by MS & Co. as a result of dealer discounts, mark-ups or other transaction costs.

Adjustments to the underlying shares or to the Nasdaq Biotechnology Index could adversely affect the value of the PLUS		Barclays Global Fund Advisors, which we refer to as BGFA, is the investment adviser to the iShares^® Nasdaq Biotechnology Index Fund, which seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the Nasdaq Biotechnology Index. Nasdaq is responsible for calculating and maintaining the Nasdaq Biotechnology Index. Nasdaq can add, delete or substitute the stocks underlying the Nasdaq Biotechnology Index or make other methodological changes that could change the value of the Nasdaq Biotechnology Index. Pursuant to its investment strategy or otherwise, BGFA may add, delete or substitute the stocks composing the iShares^® Nasdaq Biotechnology Index Fund. Any of these actions could adversely affect the price of the underlying shares and, consequently, the value of the PLUS.

The underlying shares and the Nasdaq Biotechnology Index are different		The performance of the underlying shares may not exactly replicate the performance of the Nasdaq Biotechnology Index because the iShares^® Nasdaq Biotechnology Index Fund will reflect transaction costs and fees that are not included in the

		calculation of the Nasdaq Biotechnology Index. It is also possible that the iShares^® Nasdaq Biotechnology Index Fund may not fully replicate or may in certain circumstances diverge significantly from the performance of the Nasdaq Biotechnology Index due to the temporary unavailability of certain securities in the secondary market, the performance of any derivative instruments contained in this fund or due to other circumstances. BGFA may invest up to 10% of the iShares^® Nasdaq Biotechnology Index Fund’s assets in securities not included in the Nasdaq Biotechnology Index, but which BGFA believes will help the iShares^® Nasdaq Biotechnology Index Fund track the performance of equity securities of companies in the biotechnology industry that compose the Nasdaq Biotechnology Index.

The antidilution adjustments the calculation agent is required to make do not cover every event that could affect the underlying shares		MS & Co., as calculation agent, will adjust the amount payable at maturity for certain events affecting the underlying shares. However, the calculation agent will not make an adjustment for every event that could affect the underlying shares. If an event occurs that does not require the calculation agent to adjust the amount payable at maturity, the market price of the PLUS may be materially and adversely affected.

The economic interests of the calculation agent are potentially adverse to your interests		The economic interests of the calculation agent are potentially adverse to your interests as an investor in the PLUS. As calculation agent, MS & Co. determined the initial share price and will determine the final share price and calculate the amount of cash you will receive at maturity. Determinations made by MS & Co., in its capacity as calculation agent, including with respect to the occurrence or non-occurrence of market disruption events and the calculation of the final share price (and of any antidilution adjustments), may affect the payment at maturity. See the section of this pricing supplement called “Description of PLUS—Market Disruption Event.”

		The original issue price of the PLUS includes the agent’s commissions and certain costs of hedging our obligations under the PLUS. The subsidiaries through which we hedge our obligations under the PLUS expect to make a profit. Since hedging our obligations entails risk and may be influenced by market forces beyond our or our subsidiaries’ control, such hedging may result in a profit that is more or less than initially projected.

Investing in the PLUS is not equivalent to investing in the underlying shares		Investing in the PLUS is not equivalent to investing in the underlying shares or the Nasdaq Biotechnology Index. As an investor in the PLUS, you will not have voting rights or rights to receive dividends or other distributions or any other rights with respect to the underlying shares or the stocks composing the Nasdaq Biotechnology Index.

Hedging and trading activity by the calculation agent and its affiliates could potentially adversely affect the value of the PLUS		MS & Co. and other affiliates of ours have carried out, and will continue to carry out, hedging activities related to the PLUS (and possibly to other instruments linked to the underlying shares), including trading in the underlying shares, in options contracts on the underlying shares as well as in other instruments related to the underlying shares. MS & Co. and some of our other subsidiaries also trade the underlying shares, the stocks underlying the Nasdaq Biotechnology Index and other financial instruments related to the underlying shares on a regular basis as part of their general broker-dealer and other businesses. Any of these hedging or trading activities on or prior to the day we priced the PLUS for initial sale to the public could potentially have increased the initial share price and, therefore, the price at which the underlying shares must close on the valuation date before you receive a payment at maturity that exceeds the principal amount of the PLUS. Additionally, such hedging or trading activities during the term of the PLUS could potentially

		affect the closing price of the underlying shares on the valuation date and, accordingly, the amount of cash you will receive at maturity.

There are risks associated with investments in securities with concentration in a single industry		The stocks included in the Nasdaq Biotechnology Index and that are generally tracked by the underlying shares are stocks of biotechnology or pharmaceutical companies primarily engaged in using biomedical research for the development of novel treatments or cures for human disease. The underlying shares may be subject to increased price volatility as they are linked to a single industry, market or sector and may be more susceptible to adverse economic, market, political or regulatory occurrences affecting that industry, market or sector. Industry specific risks to which companies in the biotechnology industry are subject may include the following:

		• After spending heavily on research and development, their products or services may not prove commercially successful or may become obsolete quickly;
		• The biotechnology industry may be subject to greater governmental regulation than other industries and changes in governmental policies and the need for regulatory approvals may have a material adverse effect on the industry;
		• Companies in the biotechnology industry are subject to risks of new technologies and competitive pressures; and
		• Companies in the biotechnology industry are heavily dependent on patents and intellectual property rights. The loss or impairment of these rights may adversely affect the profitability of these companies.
Although the U.S. federal income tax consequences of an investment in the PLUS are uncertain, each PLUS generally should be treated as a single financial contract that is an “open transaction” for U.S. federal income tax purposes		Although the U.S. federal income tax consequences of an investment in the PLUS are uncertain, each PLUS generally should be treated as a single financial contract that is an “open transaction” for U.S. federal income tax purposes. Please read the discussion under “United States Federal Income Taxation” in this pricing supplement concerning the U.S. federal tax consequences of investing in the PLUS. As discussed under “United States Federal Income Taxation─Tax Consequences to U.S. Holders─Tax Treatment of the PLUS─Potential Application of the Constructive Ownership Rule,” although the matter is not clear, there is a substantial risk that an investment in the PLUS will be treated as a “constructive ownership transaction.” If such treatment applies, it is not clear to what extent any long-term capital gain of the U.S. Holder in respect of the PLUS will be recharacterized as ordinary income (which ordinary income would also be subject to an interest charge). U.S. investors should consult their tax advisors regarding the potential application of the “constructive ownership” rule. If the Internal Revenue Service (the “IRS”) were successful in asserting an alternative characterization or treatment for the PLUS, the timing and character of income on the PLUS might differ significantly. We do not plan to request a ruling from the IRS regarding the tax treatment of the PLUS, and the IRS or a court may not agree with the tax treatment described in this pricing supplement.

		You are urged to consult your own tax advisors regarding all aspects of the U.S. federal tax consequences of investing in the PLUS, as well as any tax consequences arising under the laws of any state, local or foreign taxing jurisdiction.

	High	Low	Period End
2002
First Quarter	88.90	72.25	77.10
Second Quarter	77.90	47.80	51.00
Third Quarter	54.47	40.42	46.25
Fourth Quarter	56.20	44.60	49.35
2003
First Quarter	53.20	46.66	51.20
Second Quarter	75.19	50.25	66.99
Third Quarter	79.50	65.15	71.75
Fourth Quarter	75.80	65.76	71.95
2004
First Quarter	80.90	72.92	77.29
Second Quarter	84.27	72.00	75.10
Third Quarter	74.39	61.25	69.93
Fourth Quarter	75.93	65.00	75.40
2005
First Quarter	74.45	63.30	63.55
Second Quarter	68.57	63.00	67.90
Third Quarter	79.00	67.85	77.00
Fourth Quarter	79.94	70.70	77.24
2006
First Quarter	85.41	78.40	82.38
Second Quarter	81.25	69.40	72.70
Third Quarter	74.33	67.94	73.78
Fourth Quarter	81.92	73.09	77.76

2007
First Quarter	81.52	72.98	75.78
Second Quarter	83.60	75.80	78.12
Third Quarter (through September 21, 2007)	82.76	75.89	82.76

		The following graph shows the daily Closing Prices of the Underlying Shares from January 1, 2002 through September 21, 2007. We obtained the information in the graph below from Bloomberg Financial Markets, without independent verification. The historical Closing Prices should not be taken as an indication of future performance, and no assurance can be given as to the Closing Price on the Valuation date.